from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. An injectable gonadotropin-releasing hormone antagonist used to treat some hormone-sensitive cancers and gynaecological disorders.


Sorry, no etymologies found.


  • Under the terms of the agreement, if cetrorelix, which is currently in Phase 3 clinical trials for the treatment of benign prostatic hyperplasia, is approved for sale by European regulatory authorities in an indication other than in vitro fertilization, Æterna Zentaris has agreed to make a one-time cash payment to CHRP in an amount ranging from $5 million up to a maximum of $15 million. Featured News and Stories

  • The company announced the failure of a phase III trial of its cetrorelix drug for reducing symptoms of an enlarged prostrate.

    InterDigital Drops, While Align Climbs

  • The improvement came on a drop in R&D costs to $5 million from $12.1 million as the company wound down development of its cetrorelix program as well as foreign exchange gains due to the weakening of the euro versus the Canadian and U.S. dollars.

    Market News

  • AEterna Zentaris says cetrorelix did not meet goals in trial, and will focus on other drugs AEterna Zentaris says prostate drug fails in studyNEW YORK - Canadian drugmaker AEterna Zentaris Inc. said Monday its enlarged prostate drug cetrorelix did not meet its main goal in a late-stage clinical study.

    Gaea Times (by Simple Thoughts) Breaking News and incisive views 24/7

  • Æterna Zentaris announces results of its cetrorelix pamoate clinical development program TQT trial


  • Patients are administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 and are followed up to Week 52.

    Latest News from SYS-CON ITALIA

  • (EURONEXT: SAN; NYSE: SNY) for the development, registration and marketing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market.

    Latest News from SYS-CON ITALIA

  • The Netherlands, receive cetrorelix according to similar dosing regimens used in the first study.

    Latest News from SYS-CON ITALIA

  • Patients are then randomly allocated to cetrorelix or placebo in a double-blind fashion.

    Latest News from SYS-CON ITALIA

  • Then, in an open-label extension, patients receive cetrorelix by IM injection at Week 52, 54, 78 and 80 and are followed up to Week 90.

    Latest News from SYS-CON ITALIA


Log in or sign up to get involved in the conversation. It's quick and easy.